The anti-cancer efficacy of PgP/pHSV-TK polyplexes with both GCV doses of 50 and 100 μg/mL was significantly higher than that of PgP/pGFP polyplexes at both 1 and 4 days post-treatment. The gene discussed is PGP; the disease is cancer.